1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Molecular Diagnostics in Point of Care Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Polymerase Chain Reaction
1.2.3 In Situ Hybridization
1.2.4 Gene Chips
1.2.5 Next Generation Sequencing
1.3 Market by Application
1.3.1 Global Molecular Diagnostics in Point of Care Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospitals and Clinics
1.3.3 Independent Clinical Laboratories
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Molecular Diagnostics in Point of Care Market Perspective (2017-2028)
2.2 Molecular Diagnostics in Point of Care Growth Trends by Region
2.2.1 Molecular Diagnostics in Point of Care Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Molecular Diagnostics in Point of Care Historic Market Size by Region (2017-2022)
2.2.3 Molecular Diagnostics in Point of Care Forecasted Market Size by Region (2023-2028)
2.3 Molecular Diagnostics in Point of Care Market Dynamics
2.3.1 Molecular Diagnostics in Point of Care Industry Trends
2.3.2 Molecular Diagnostics in Point of Care Market Drivers
2.3.3 Molecular Diagnostics in Point of Care Market Challenges
2.3.4 Molecular Diagnostics in Point of Care Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Molecular Diagnostics in Point of Care Players by Revenue
3.1.1 Global Top Molecular Diagnostics in Point of Care Players by Revenue (2017-2022)
3.1.2 Global Molecular Diagnostics in Point of Care Revenue Market Share by Players (2017-2022)
3.2 Global Molecular Diagnostics in Point of Care Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Molecular Diagnostics in Point of Care Revenue
3.4 Global Molecular Diagnostics in Point of Care Market Concentration Ratio
3.4.1 Global Molecular Diagnostics in Point of Care Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Molecular Diagnostics in Point of Care Revenue in 2021
3.5 Molecular Diagnostics in Point of Care Key Players Head office and Area Served
3.6 Key Players Molecular Diagnostics in Point of Care Product Solution and Service
3.7 Date of Enter into Molecular Diagnostics in Point of Care Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Molecular Diagnostics in Point of Care Breakdown Data by Type
4.1 Global Molecular Diagnostics in Point of Care Historic Market Size by Type (2017-2022)
4.2 Global Molecular Diagnostics in Point of Care Forecasted Market Size by Type (2023-2028)
5 Molecular Diagnostics in Point of Care Breakdown Data by Application
5.1 Global Molecular Diagnostics in Point of Care Historic Market Size by Application (2017-2022)
5.2 Global Molecular Diagnostics in Point of Care Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Molecular Diagnostics in Point of Care Market Size (2017-2028)
6.2 North America Molecular Diagnostics in Point of Care Market Size by Country (2017-2022)
6.3 North America Molecular Diagnostics in Point of Care Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Molecular Diagnostics in Point of Care Market Size (2017-2028)
7.2 Europe Molecular Diagnostics in Point of Care Market Size by Country (2017-2022)
7.3 Europe Molecular Diagnostics in Point of Care Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Molecular Diagnostics in Point of Care Market Size (2017-2028)
8.2 Asia-Pacific Molecular Diagnostics in Point of Care Market Size by Country (2017-2022)
8.3 Asia-Pacific Molecular Diagnostics in Point of Care Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Molecular Diagnostics in Point of Care Market Size (2017-2028)
9.2 Latin America Molecular Diagnostics in Point of Care Market Size by Country (2017-2022)
9.3 Latin America Molecular Diagnostics in Point of Care Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Molecular Diagnostics in Point of Care Market Size (2017-2028)
10.2 Middle East & Africa Molecular Diagnostics in Point of Care Market Size by Country (2017-2022)
10.3 Middle East & Africa Molecular Diagnostics in Point of Care Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Detail
11.1.2 Abbott Business Overview
11.1.3 Abbott Molecular Diagnostics in Point of Care Introduction
11.1.4 Abbott Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.1.5 Abbott Recent Development
11.2 Accelerate Diagnostics
11.2.1 Accelerate Diagnostics Company Detail
11.2.2 Accelerate Diagnostics Business Overview
11.2.3 Accelerate Diagnostics Molecular Diagnostics in Point of Care Introduction
11.2.4 Accelerate Diagnostics Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.2.5 Accelerate Diagnostics Recent Development
11.3 Ador Diagnostics
11.3.1 Ador Diagnostics Company Detail
11.3.2 Ador Diagnostics Business Overview
11.3.3 Ador Diagnostics Molecular Diagnostics in Point of Care Introduction
11.3.4 Ador Diagnostics Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.3.5 Ador Diagnostics Recent Development
11.4 Beckman Coulter
11.4.1 Beckman Coulter Company Detail
11.4.2 Beckman Coulter Business Overview
11.4.3 Beckman Coulter Molecular Diagnostics in Point of Care Introduction
11.4.4 Beckman Coulter Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.4.5 Beckman Coulter Recent Development
11.5 Becton, Dickinson and Company
11.5.1 Becton, Dickinson and Company Company Detail
11.5.2 Becton, Dickinson and Company Business Overview
11.5.3 Becton, Dickinson and Company Molecular Diagnostics in Point of Care Introduction
11.5.4 Becton, Dickinson and Company Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.5.5 Becton, Dickinson and Company Recent Development
11.6 Binx Health
11.6.1 Binx Health Company Detail
11.6.2 Binx Health Business Overview
11.6.3 Binx Health Molecular Diagnostics in Point of Care Introduction
11.6.4 Binx Health Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.6.5 Binx Health Recent Development
11.7 Biocartis
11.7.1 Biocartis Company Detail
11.7.2 Biocartis Business Overview
11.7.3 Biocartis Molecular Diagnostics in Point of Care Introduction
11.7.4 Biocartis Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.7.5 Biocartis Recent Development
11.8 bioM?(C)rieux
11.8.1 bioM?(C)rieux Company Detail
11.8.2 bioM?(C)rieux Business Overview
11.8.3 bioM?(C)rieux Molecular Diagnostics in Point of Care Introduction
11.8.4 bioM?(C)rieux Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.8.5 bioM?(C)rieux Recent Development
11.9 Bio-Rad Laboratories
11.9.1 Bio-Rad Laboratories Company Detail
11.9.2 Bio-Rad Laboratories Business Overview
11.9.3 Bio-Rad Laboratories Molecular Diagnostics in Point of Care Introduction
11.9.4 Bio-Rad Laboratories Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.9.5 Bio-Rad Laboratories Recent Development
11.10 Bosch Healthcare Solutions
11.10.1 Bosch Healthcare Solutions Company Detail
11.10.2 Bosch Healthcare Solutions Business Overview
11.10.3 Bosch Healthcare Solutions Molecular Diagnostics in Point of Care Introduction
11.10.4 Bosch Healthcare Solutions Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.10.5 Bosch Healthcare Solutions Recent Development
11.11 Curetis
11.11.1 Curetis Company Detail
11.11.2 Curetis Business Overview
11.11.3 Curetis Molecular Diagnostics in Point of Care Introduction
11.11.4 Curetis Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.11.5 Curetis Recent Development
11.12 Eurofins Scientific
11.12.1 Eurofins Scientific Company Detail
11.12.2 Eurofins Scientific Business Overview
11.12.3 Eurofins Scientific Molecular Diagnostics in Point of Care Introduction
11.12.4 Eurofins Scientific Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.12.5 Eurofins Scientific Recent Development
11.13 Genetic Signatures
11.13.1 Genetic Signatures Company Detail
11.13.2 Genetic Signatures Business Overview
11.13.3 Genetic Signatures Molecular Diagnostics in Point of Care Introduction
11.13.4 Genetic Signatures Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.13.5 Genetic Signatures Recent Development
11.14 Grifols
11.14.1 Grifols Company Detail
11.14.2 Grifols Business Overview
11.14.3 Grifols Molecular Diagnostics in Point of Care Introduction
11.14.4 Grifols Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.14.5 Grifols Recent Development
11.15 Hibergene Diagnostics
11.15.1 Hibergene Diagnostics Company Detail
11.15.2 Hibergene Diagnostics Business Overview
11.15.3 Hibergene Diagnostics Molecular Diagnostics in Point of Care Introduction
11.15.4 Hibergene Diagnostics Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.15.5 Hibergene Diagnostics Recent Development
11.16 Lumos Diagnostics
11.16.1 Lumos Diagnostics Company Detail
11.16.2 Lumos Diagnostics Business Overview
11.16.3 Lumos Diagnostics Molecular Diagnostics in Point of Care Introduction
11.16.4 Lumos Diagnostics Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.16.5 Lumos Diagnostics Recent Development
11.17 Roche
11.17.1 Roche Company Detail
11.17.2 Roche Business Overview
11.17.3 Roche Molecular Diagnostics in Point of Care Introduction
11.17.4 Roche Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.17.5 Roche Recent Development
11.18 Siemens
11.18.1 Siemens Company Detail
11.18.2 Siemens Business Overview
11.18.3 Siemens Molecular Diagnostics in Point of Care Introduction
11.18.4 Siemens Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.18.5 Siemens Recent Development
11.19 Thermo Fisher Scientific
11.19.1 Thermo Fisher Scientific Company Detail
11.19.2 Thermo Fisher Scientific Business Overview
11.19.3 Thermo Fisher Scientific Molecular Diagnostics in Point of Care Introduction
11.19.4 Thermo Fisher Scientific Revenue in Molecular Diagnostics in Point of Care Business (2017-2022)
11.19.5 Thermo Fisher Scientific Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details